Asier SÃ¡ez-CiriÃ³n

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8333208/publications.pdf

Version: 2024-02-01

98	5,323	117625	88630
papers	citations	34 h-index	70 g-index

104	104	104	5793
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study. PLoS Pathogens, 2013, 9, e1003211.	4.7	879
2	HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 6776-6781.	7.1	553
3	International AIDS Society global scientific strategy: towards an HIV cure 2016. Nature Medicine, 2016, 22, 839-850.	30.7	395
4	Antigen sensitivity is a major determinant of CD8+ T-cell polyfunctionality and HIV-suppressive activity. Blood, 2009, 113, 6351-6360.	1.4	192
5	Heterogeneity in HIV Suppression by CD8 T Cells from HIV Controllers: Association with Gag-Specific CD8 T Cell Responses. Journal of Immunology, 2009, 182, 7828-7837.	0.8	183
6	HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report. Lancet HIV,the, 2016, 3, e49-e54.	4.7	131
7	Cellular Metabolism Is a Major Determinant of HIV-1 Reservoir Seeding in CD4+ T Cells and Offers an Opportunity to Tackle Infection. Cell Metabolism, 2019, 29, 611-626.e5.	16.2	124
8	Sphingomyelin and Cholesterol Promote HIV-1 gp41 Pretransmembrane Sequence Surface Aggregation and Membrane Restructuring. Journal of Biological Chemistry, 2002, 277, 21776-21785.	3.4	119
9	Restriction of HIV-1 replication in macrophages and CD4+ T cells from HIV controllers. Blood, 2011, 118, 955-964.	1.4	107
10	Clinical and public health implications of acute and early HIV detection and treatment: a scoping review. Journal of the International AIDS Society, 2017, 20, 21579.	3.0	107
11	HIV cure research: Advances and prospects. Virology, 2014, 454-455, 340-352.	2.4	103
12	Replication-competent HIV strains infect HIV controllers despite undetectable viremia (ANRS EP36) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.2	94
13	HIV controllers: how do they tame the virus?. Trends in Immunology, 2007, 28, 532-540.	6.8	94
14	Combined ART started during acute HIV infection protects central memory CD4+ T cells and can induce remission. Journal of Antimicrobial Chemotherapy, 2015, 70, 2108-2120.	3.0	92
15	Potential Role for HIV-Specific CD38â˜'/HLA-DR+ CD8+ T Cells in Viral Suppression and Cytotoxicity in HIV Controllers. PLoS ONE, 2014, 9, e101920.	2.5	90
16	The pre-transmembrane region of the human immunodeficiency virus type-1 glycoprotein: a novel fusogenic sequence. FEBS Letters, 2000, 477, 145-149.	2.8	88
17	Elevated IP10 levels are associated with immune activation and low CD4+ T-cell counts in HIV controller patients. Aids, 2014, 28, 467-476.	2.2	85
18	p21-mediated RNR2 repression restricts HIV-1 replication in macrophages by inhibiting dNTP biosynthesis pathway. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E3997-4006.	7.1	83

#	Article	IF	Citations
19	Structural and Functional Roles of HIV-1 gp41 Pretransmembrane Sequence Segmentation. Biophysical Journal, 2003, 85, 3769-3780.	0.5	79
20	High Antibody-Dependent Cellular Cytotoxicity Responses Are Correlated with Strong CD8 T Cell Viral Suppressive Activity but Not with B57 Status in HIV-1 Elite Controllers. PLoS ONE, 2013, 8, e74855.	2.5	76
21	Metabolic plasticity of HIV-specific CD8+ T cells is associated with enhanced antiviral potential and natural control of HIV-1 infection. Nature Metabolism, 2019, 1, 704-716.	11.9	72
22	Ex vivo T cellâ€“based HIV suppression assay to evaluate HIV-specific CD8+ T-cell responses. Nature Protocols, 2010, 5, 1033-1041.	12.0	69
23	Ultrasensitive HIV-1 p24 Assay Detects Single Infected Cells and Differences in Reservoir Induction by Latency Reversal Agents. Journal of Virology, 2017, 91, .	3.4	64
24	Interfacial pre-transmembrane domains in viral proteins promoting membrane fusion and fission. Biochimica Et Biophysica Acta - Biomembranes, 2008, 1778, 1624-1639.	2.6	61
25	<scp>HIV</scp> controllers: a genetically determined or inducible phenotype?. Immunological Reviews, 2013, 254, 281-294.	6.0	57
26	Conformational transitions of membrane-bound HIV-1 fusion peptide. Biochimica Et Biophysica Acta - Biomembranes, 2002, 1564, 57-65.	2.6	56
27	Immunometabolism and HIV-1 pathogenesis: food for thought. Nature Reviews Immunology, 2021, 21, 5-19.	22.7	55
28	CD4 Dynamics over a 15 Year-Period among HIV Controllers Enrolled in the ANRS French Observatory. PLoS ONE, 2011, 6, e18726.	2.5	52
29	Elevated Basal Pre-infection CXCL10 in Plasma and in the Small Intestine after Infection Are Associated with More Rapid HIV/SIV Disease Onset. PLoS Pathogens, 2016, 12, e1005774.	4.7	50
30	Long-Term Spontaneous Control of HIV-1 Is Related to Low Frequency of Infected Cells and Inefficient Viral Reactivation. Journal of Virology, 2016, 90, 6148-6158.	3.4	50
31	Immunologic and Virologic Progression in HIV Controllers: The Role of Viral â€œBlipsâ€•and Immune Activation in the ANRS CO21 CODEX Study. PLoS ONE, 2015, 10, e0131922.	2.5	50
32	A Subset of Extreme Human Immunodeficiency Virus (HIV) Controllers Is Characterized by a Small HIV Blood Reservoir and a Weak T-Cell Activation Level. Open Forum Infectious Diseases, 2017, 4, ofx064.	0.9	45
33	Pre-transmembrane sequence of Ebola glycoprotein. FEBS Letters, 2003, 533, 47-53.	2.8	39
34	Both HLA-B*57 and Plasma HIV RNA Levels Contribute to the HIV-Specific CD8 ⁺ T Cell Response in HIV Controllers. Journal of Virology, 2014, 88, 176-187.	3.4	39
35	Immune Responses to Retroviruses. Annual Review of Immunology, 2018, 36, 193-220.	21.8	36
36	Natural Resistance to HIV Infection: Lessons Learned from HIVâ€Exposed Uninfected Individuals. Journal of Infectious Diseases, 2010, 202, S345-S350.	4.0	34

#	Article	IF	Citations
37	Blunted Response to Combination Antiretroviral Therapy in HIV Elite Controllers: An International HIV Controller Collaboration. PLoS ONE, 2014, 9, e85516.	2.5	34
38	The Engagement of Activating FcÎ³Rs Inhibits Primate Lentivirus Replication in Human Macrophages. Journal of Immunology, 2006, 177, 6291-6300.	0.8	33
39	Antibodies attenuate the capacity of dendritic cells to stimulate HIV-specific cytotoxic T lymphocytes. Journal of Allergy and Clinical Immunology, 2012, 130, 1368-1374.e2.	2.9	33
40	Equilibrium and Kinetic Studies of the Solubilization of Phospholipidâˆ'Cholesterol Bilayers by C12E8. The Influence of the Lipid Phase Structure. Langmuir, 2000, 16, 1960-1968.	3.5	29
41	HIV-1 Envelope Overcomes NLRP3-Mediated Inhibition of F-Actin Polymerization for Viral Entry. Cell Reports, 2019, 28, 3381-3394.e7.	6.4	28
42	p21 Restricts HIV-1 in Monocyte-Derived Dendritic Cells through the Reduction of Deoxynucleoside Triphosphate Biosynthesis and Regulation of SAMHD1 Antiviral Activity. Journal of Virology, 2017, 91, .	3.4	27
43	Polyfunctional HIV-specific T cells in Post-Treatment Controllers. Aids, 2016, 30, 2299-2302.	2.2	26
44	Immune responses during spontaneous control of HIV and AIDS: what is the hope for a cure?. Philosophical Transactions of the Royal Society B: Biological Sciences, 2014, 369, 20130436.	4.0	24
45	High Eomesodermin Expression among CD57 ⁺ CD8 ⁺ T Cells Identifies a CD8 ⁺ T Cell Subset Associated with Viral Control during Chronic Human Immunodeficiency Virus Infection. Journal of Virology, 2014, 88, 11861-11871.	3.4	24
46	Posttreatment controllers. Current Opinion in HIV and AIDS, 2015, 10, 29-34.	3.8	24
47	HIV Controllers Have Low Inflammation Associated with a Strong HIV-Specific Immune Response in Blood. Journal of Virology, 2019, 93, .	3.4	24
48	SIV-induced terminally differentiated adaptive NK cells in lymph nodes associated with enhanced MHC-E restricted activity. Nature Communications, 2021, 12, 1282.	12.8	24
49	Immediate T-Helper 17 Polarization Upon Triggering CD11b/c on HIV-Exposed Dendritic Cells. Journal of Infectious Diseases, 2015, 212, 44-56.	4.0	22
50	CD8 T-Cells from Most HIV-Infected Patients Lack Ex Vivo HIV-Suppressive Capacity during Acute and Early Infection. PLoS ONE, 2013, 8, e59767.	2.5	21
51	Long-Term Control of Simian Immunodeficiency Virus (SIV) in Cynomolgus Macaques Not Associated with Efficient SIV-Specific CD8⁺T-Cell Responses. Journal of Virology, 2015, 89, 3542-3556.	3.4	21
52	Dynamics in HIVâ€ÐNA levels over time in HIV controllers. Journal of the International AIDS Society, 2019, 22, e25221.	3.0	21
53	Preservation of Lymphopoietic Potential and Virus Suppressive Capacity by CD8+ T Cells in HIV-2â€"Infected Controllers. Journal of Immunology, 2016, 197, 2787-2795.	0.8	19
54	Persistent resistance to HIV-1 infection in CD4 T cells from exposed uninfected Vietnamese individuals is mediated by entry and post-entry blocks. Retrovirology, 2006, 3, 81.	2.0	18

#	Article	IF	Citations
55	Extremely low viral reservoir in treated chronically HIV-1-infected individuals. EBioMedicine, 2020, 57, 102830.	6.1	18
56	Dendritic Cells from HIV Controllers Have Low Susceptibility to HIV-1 Infection In Vitro but High Capacity to Capture HIV-1 Particles. PLoS ONE, 2016, 11, e0160251.	2.5	18
57	Vulnerability to reservoir reseeding due to high immune activation after allogeneic hematopoietic stem cell transplantation in individuals with HIV-1. Science Translational Medicine, 2020, 12, .	12.4	17
58	Ku80 Participates in the Targeting of Retroviral Transgenes to the Chromatin of CHO Cells. Journal of Virology, 2007, 81, 7924-7932.	3.4	15
59	Reply to Pauls et al.: p21 is a master regulator of HIV replication in macrophages through dNTP synthesis block. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E1325-6.	7.1	15
60	Reprogramming dysfunctional CD8+ T cells to promote properties associated with natural HIV control. Journal of Clinical Investigation, 2022, 132, .	8.2	15
61	Sphingolipids (Galactosylceramide and Sulfatide) in Lamellarâ^'Hexagonal Phospholipid Phase Transitions and in Membrane Fusionâ€. Langmuir, 2000, 16, 8958-8963.	3.5	14
62	The Hydrophobic Internal Region of Bovine Prion Protein Shares Structural and Functional Properties with HIV Type 1 Fusion Peptide. AIDS Research and Human Retroviruses, 2003, 19, 969-978.	1.1	14
63	HLA-B*14:02-Restricted Env-Specific CD8 + T-Cell Activity Has Highly Potent Antiviral Efficacy Associated with Immune Control of HIV Infection. Journal of Virology, 2017, 91, .	3.4	14
64	HIV controllers: to treat or not to treat? Is that the right question?. Lancet HIV,the, 2019, 6, e878-e884.	4.7	13
65	Safety of CD34+ Hematopoietic Stem Cells and CD4+ T Lymphocytes Transduced with LVsh5/C46 in HIV-1 Infected Patients with High-Risk Lymphoma. Molecular Therapy - Methods and Clinical Development, 2019, 13, 303-309.	4.1	13
66	The Genome-wide Methylation Profile of CD4+ T Cells From Individuals With Human Immunodeficiency Virus (HIV) Identifies Distinct Patterns Associated With Disease Progression. Clinical Infectious Diseases, 2021, 72, e256-e264.	5.8	13
67	Immunovirologic Control 24 Months After Interruption of Antiretroviral Therapy Initiated Close to HIV Seroconversion. JAMA Internal Medicine, 2013, 173, 475.	5.1	12
68	Optimal Maturation of the SIV-Specific CD8+ T Cell Response after Primary Infection Is Associated with Natural Control of SIV: ANRS SIC Study. Cell Reports, 2020, 32, 108174.	6.4	12
69	Quantitative real-time analysis of HIV-1 gene expression dynamics in single living primary cells. Biotechnology Journal, 2006, 1, 682-689.	3.5	11
70	Immunodominance of HLA-B27-restricted HIV KK10-specific CD8+ T-cells is not related to naÃ¯ve precursor frequency. Immunology Letters, 2013, 149, 119-122.	2.5	11
71	The link between CD8+ T-cell antigen-sensitivity and HIV-suppressive capacity depends on HLA restriction, target epitope and viral isolate. Aids, 2014, 28, 477-486.	2.2	10
72	Affinity for the Interface Underpins Potency of Antibodies Operating In Membrane Environments. Cell Reports, 2020, 32, 108037.	6.4	10

#	Article	IF	Citations
73	SUGT1 controls susceptibility to HIV-1 infection by stabilizing microtubule plus-ends. Cell Death and Differentiation, 2020, 27, 3243-3257.	11.2	10
74	Novel role of UHRF1 in the epigenetic repression of the latent HIV-1. EBioMedicine, 2022, 79, 103985.	6.1	10
75	Ultrasensitive Detection of p24 in Plasma Samples from People with Primary and Chronic HIV-1 Infection. Journal of Virology, 2021, 95, e0001621.	3.4	9
76	Transient viral exposure drives functionally-coordinated humoral immune responses in HIV-1 post-treatment controllers. Nature Communications, 2022, 13, 1944.	12.8	9
77	Role of NKG2a/c+CD8+ TÂcells in pathogenic versus non-pathogenic SIV infections. IScience, 2021, 24, 102314.	4.1	8
78	CD32+CD4+ T Cells Sharing B Cell Properties Increase With Simian Immunodeficiency Virus Replication in Lymphoid Tissues. Frontiers in Immunology, 2021, 12, 695148.	4.8	8
79	Strong ifitm1 Expression in CD4 T Cells in HIV Controllers Is Correlated With Immune Activation. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, e56-e59.	2.1	7
80	Will it be possible to live without antiretroviral therapy?. Current Opinion in HIV and AIDS, 2013, 8, 196-203.	3.8	5
81	NKG2D Expression on HIV-Specific CD8+ T cells Is Reduced in Viremic HIV-1â€“Infected Patients but Maintained in HIV Controllers. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 17-20.	2.1	5
82	What is the significance of posttreatment control of HIV infection vis-Ã-vis functional cure?. Aids, 2014, 28, 603-605.	2.2	5
83	Cellular Determinants of HIV Persistence on Antiretroviral Therapy. Advances in Experimental Medicine and Biology, 2018, 1075, 213-239.	1.6	5
84	Antiretroviral therapy for HIV controllers: Reasons for initiation and outcomes in the French ANRS-CO21 CODEX cohort. EClinicalMedicine, 2021, 37, 100963.	7.1	5
85	A system and methodology for high-content visual screening of individual intact living cells in suspension. , 2007, , .		4
86	Definition, Natural History and Heterogeneity of HIV Controllers. , 2012, , 233-252.		4
87	Kidney transplantation in an elite HIV controller: Limited impact of immunosuppressive therapy on viro-immunological status. Journal of Infection, 2012, 64, 630-633.	3.3	4
88	The Yellow Brick Road towards HIV Eradication. Trends in Immunology, 2019, 40, 465-467.	6.8	4
89	Initiating Antiretroviral Treatment Early in Infancy Has Long-term Benefits on the Human Immunodeficiency Virus Reservoir in Late Childhood and Adolescence. Clinical Infectious Diseases, 2021, 73, e4214-e4222.	5.8	4
90	Antiapoptotic Clone 11-Derived Peptides Induce In Vitro Death of CD4 ⁺ T Cells Susceptible to HIV-1 Infection. Journal of Virology, 2020, 94, .	3.4	3

#	Article	IF	Citations
91	Saporin-conjugated tetramers identify efficacious anti-HIV CD8+ T-cell specificities. PLoS ONE, 2017, 12, e0184496.	2.5	2
92	The characteristic CD8+ T cell response in HIV controllers: An objective to achieve?. Pathologie Et Biologie, 2008, 56, 251-253.	2.2	1
93	The proportion of CD57+ cells among effector CD8+ T cells is lower in HIV controllers compared with antiretroviral therapy-treated patients. Aids, 2019, 33, 2137-2147.	2.2	1
94	Post-treatment Controllers. , 2018, , 1655-1659.		1
95	NK cell spatial dynamics and IgA responses in gut-associated lymphoid tissues during SIV infections. Communications Biology, 2022, 5, .	4.4	1
96	The role of cytotoxic T cells. Retrovirology, 2010, 7, .	2.0	0
97	RNR2 repression by p21 restricts reverse transcription of HIV-1 and related-lentiviruses in macrophages. Retrovirology, 2013, 10, .	2.0	0
98	Post-treatment Controllers. , 2014, , 1-6.		0